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1. Introduction
A peroxisome is a ubiquitous, spherical, intra-
cellular organelle bounded by a single membrane and
having a diameter of 0.1–1 mm in eukaryotes, which
is defined as an organelle containing at least one
H2O2-producing oxidase and H O -decomposing2 2
w xcatalase 1 . Peroxisomes function in a wide variety
of metabolic pathways including catabolism of very-
 .long chain fatty acids VLCFAs by b-oxidation;
biosynthesis of ether-linked glycerolipids such as
plasmalogens, structural ether lipids abundunt in the
central nervous system; interconversion of cholesterol
Abbreviations: ALDP, adrenoleukodystrophy protein; AOX,
acyl-CoA oxidase; CAT, chloramphenicol acetyltransferase;
CHO, Chinese hamster ovary; DHAP-ATase, dihydroxyace-
tonephosphate acyltransferase; EST, expressed sequence tag; IRD,
infantile Refsum disease; NALD, neonatal adrenoleukodystrophy;
 X .  X .P9OH, 9- 1-pyrene nonanol; P12, 12- 1-pyrene dodecanoicacid;
PAF-1 and PAF-2, peroxisome assembly factor-1 and -2, respec-
tively; PCR, polymerase chain reaction; PH1, hyperoxaluria type
1; PMP70, 70-kDa peroxisomal integral membrane protein; PTS1
and PTS2, peroxisomal targeting signal type 1 and type 2,
respectively; RCDP, rhizomelic chondrodysplasia punctata; TPR,
tetratricopeptide repeat; UV, long wavelength ultraviolet; VL-
CFA, very long chain fatty acid; ZS, Zellweger syndrome; X-
ALD, X-linked adrenoleukodystrophy
) Fax: q81 92 6424214 or 2645. E-mail:
yfujiscb@mbox.nc.kyushu-u.ac.jp
wto bile acids; and glyoxylate transamination for a
w xxreview, see Ref. 2 .
Several features unique to peroxisomes include
massive protein induction and organelle proliferation.
The treatment of rats with hypolipidemic drugs or
plasticizers allows peroxisomes to proliferate and
also induces peroxisomal proteins, including enzymes
w xof the fatty acid b-oxidation system 3,4 .
 .Peroxisome proliferator activated receptors PPAR
 .form a heterodimer with retinol X receptor RXR
and bind to the peroxisome proliferator responsive
elements comprised of direct repeats of the consensus
sequence TGACCT separated by one base pair,
thereby enhancing the transcription of genes for per-
w xoxisomal proteins 5–7 . Recently, bona fide natural
ligands of two subtypes of PPARs, PPAR a and
PPARg , have been identified, namely: leukotriene B4
w xfor PPAR a 8 and a prostaglandin J metabolite for2
w xPPARg 9,10 . In various types of yeast including
several Candida species, Hansenula polymorpha,
Saccharomyces cere˝isiae, Pichia pastoris, and
Yarrowia lipolytica, oleic acid andror methanol in-
duce a massive proliferation of peroxisomes with
highly elevated levels of methanol utilization and a
w xfatty acid b-oxidation system 11–15 . Many genes
encoding peroxisomal soluble and membrane proteins
have been cloned by taking advantage of such induc-
tive properties.
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The functional significance of human peroxisomes
is highlighted by fatal genetic diseases linked to both
a peroxisomal malfunction and a failure of peroxi-
some biogenesis. Among the disorders showing an
 .absence of peroxisomes, Zellweger syndrome ZS is
a typical, severe disease. Patients with ZS rarely
w xsurvive beyond 6 months 16,17 . Studies on both
peroxisomal disorders and peroxisome biogenesis are
rapidly progressing, particularly by means of molecu-
lar, cell biological, and genetic approaches using
yeast and mammalian cell mutants defective in perox-
isome biogenesis. These studies have led to the iden-
 .tification of peroxisomal targeting signals PTSs , the
isolation of a number of genes essential for peroxi-
some assembly in both yeast and mammalian cells,
and the discovery of the primary defects in several
w xperoxisomal diseases 18–21 .
This review describes the recent progress in the
study of the genetic causes of peroxisomal disorders,
especially in connection with the molecular mecha-
nisms of peroxisome biogenesis.
2. Biogenesis of peroxisomes
Peroxisomes are formed by the division of preex-
isting peroxisomes after the posttranslational import
w xof newly synthesized proteins 22 . Peroxisomal pro-
teins, including membrane proteins, are synthesized
on free polyribosomes in the cytosol, mostly at their
final sizes, and are posttranslationally translocated
w xinto peroxisomes 22 . Synthesis at their mature sizes
 .implies that the topogenic signal s for the transport
of newly synthesized proteins into peroxisomes re-
w xside in the internal sequences of the proteins 23 .
The recent findings on cis-acting PTSs are discussed
below and they have been reported in several reviews
w x18–21,23–25 The import into peroxisomes of newly
synthesized polypeptides requires energy in the form
w xof ATP 26–28 , as well as perhaps a proton motive
w x w xforce 29 , the chaperonin Hsp70 30 and divalent
w xions 26,31 .
Recent observations regarding the translocation of
polypeptides across the peroxisomal membrane ap-
parently contradict with the general paradigm that
proteins are translocated in an unfolded state. Mi-
croinjected, chemically crosslinked proteins and col-
loidal gold particles, conjugated to the SKL peroxiso-
 .mal targeting signal PTS1, see below are translo-
w xcated into peroxisomes in cultured cells 32 . The
cytosolic protein, chloramphenicol acetytransferase
 .CAT , was co-imported into yeast peroxisomes when
co-expressed with CAT fused to PTS1, where trimer-
ization of CAT apparently precedes the import in the
w xcytosol 33 . Likewise, a dimeric form of 3-ketoacyl-
CoA thiolase is translocated into the peroxisomes in
w xyeast 34 . An oligomeric import hypothesis that per-
oxisomes take up folded and oligomeric proteins is
intriguing, but we should await further investigation
to demonstrate how physiologically significant such
an import pathway is.
3. Topogenic signals of peroxisomal proteins
( )3.1. Carboxyl-terminal SKL motif signal PTS1
PTSs have been identified primarily by two mutu-
ally complementary systems, i.e. in vitro posttrans-
w xlational protein import into peroxisomes 26,31,35,36
and in vivo cell culture combined with recombinant
w xDNA transfection 37,38 . In vitro transcribed and
translated, radiolabeled products of cDNAs encoding
 .full length and truncated acyl-CoA oxidase AOX of
rat liver as well as its chimera proteins were incu-
w xbated with purified rat liver peroxisomes 31,36 . The
degree of peroxisomal import was assessed by the
resistance of the polypeptides to proteolysis by exter-
w xnally added protease, Proteinase K. Miura et al. 36
concluded from these results that the carboxyl-termi-
nal tripeptide SKL and its variants are sufficient to
target polypeptides to peroxisomes. In CV-1 cells, the
SKL directed fusion proteins to peroxisomes, when
linked to the carboxyl termini of cytosolic proteins
w xsuch as dihydrofolate reductase and CAT 37 . This
suggested that the tripeptide SKL functions in vivo as
a PTS, where certain conservative substitutions in the
SKL are permitted in vivo without any loss of target-
ing activity.
These investigations, both in vivo and in vitro, led
researchers to reach the same conclusions on the
C-terminal PTS: the consensus sequence for PTS1
 . can be defined as -SrArC-KrRrH-Lr M Table
.1 . The PTS1, SKL motif is found at the C-termini of
several purified mature enzymes such as porcine
w xkidney D-amino acid oxidase 39 , thus indicating that
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Table 1
Peroxisomal targeting signals
Amino acid residues indispensable for targeting activity of the
thiolase presequences are shaded.
w xPTS1 is an uncleaved topogenic signal 36 . A short,
uncleaved and well conserved targeting signal is rather
unique, in contrast to the topogenic signals for other
organelles. The SKL sequence functions not only as a
w xPTS in animals, plants, and yeast 40 , but also as a
targeting signal to the glycosome, a member of the
peroxisome family, of a unicellular parasite, the Try-
w xpanosome 41,42 , thereby implying that the mecha-
nism of protein translocation into peroxisomes using
the SKL motif has been conserved throughout eu-
w xkaryotic evolution 18,20,21,23–25,36 . As a glyco-
somal targeting signal, however, a much broader
w xspectrum of the tripeptide sequence is accepted 42 .
Very recently, the extreme C-terminal tetrapeptide,
-KNAL, of human catalase has been shown to be a
PTS similar to but apparently distinct from the SKL
w xPTS1 43 .
PTS1, tripeptide PTS motifs can be found in nearly
40% of all peroxisomal proteins so far sequenced
w x18–21,23–25 , thus suggesting the presence of other
types of PTS.
3.2. Amino-terminal peroxisomal targeting signal
( )PTS2
Several peroxisomal polypeptides are synthesized
as larger precursors with N-terminal extensions, in-
wcluding rat and human 3-ketoacyl-CoA thiolase 44–
x 47 , nonspecific lipid transfer protein sterol carrier
. w x w xprotein 2 of rat 48–50 , mouse 51 , and human
w x w x52 , watermelon malate dehydrogenase 53 , and
w xamine oxidase of H. polymorpha 54 . Two types of
peroxisomal 3-ketoacyl-CoA thiolase with N-terminal
extensions of 26 and 36 amino acids are derived from
 .the thiolase genes B and A, respectively Table 1
w x46 . These N-terminal presequences of 26 and 36
amino acids were shown to target reporter proteins to
peroxisomes in vivo using Chinese hamster ovary
 .CHO and CV-1 cells, when positioned at the N-
w xtermini of dihydrofolate reductase and CAT 55–57 .
The charged residues, arginine at position y24 start-
 .ing at the N-terminal residue of mature thiolase as 1
and histidine at y17 in the B-type were both indis-
pensable and not replaceable even by other basic
w xamino acids 55,56 . Thus, this second type of peroxi-
 .some translocation signal PTS2 has a consensus
 . .  . .sequence, - RrK LrVrI X HrQ LrA - located5
at positions 2 to 12 from the N-terminus. In yeast, S.
cere˝isiae, N-terminal 16 amino acids were shown to
act as a PTS2, although this sequence does not appear
w xto be cleaved 58,59 .Therefore, only two types of
PTS, PTS1 and PTS2, have been so far elucidated. It
is quite plausible to assume that other types of perox-
isomal translocation signals exist but only remain to
be identified. Internal PTSs have been found in AOX
of the yeast Candida tropicalis but are not yet fully
w xcharacterized 60,61 . Two independent, C-terminal
and internal, PTSs have been identified in catalase A
w xof S. cere˝isiae 62 . It is also noteworthy that the 20
amino-acid loop of a peroxisomal membrane protein,
Pmp47, of Candida boidinii contains sufficient infor-
w xmation for targeting the peroxisomal membrane 63 .
4. Peroxisomal targeting signal receptor
4.1. PTS1 receptor
In the above described study of in vitro AOX
import, a wild-type synthetic peptide comprising the
C-terminal ten amino acid residues of AOX, KHLK-
w xPLQSKL-COOH, inhibited AOX import 36 . In con-
trast, other peptides such as those with an SKL-dele-
tion, an aminated a-carboxy group, or SKL posi-
tioned in the middle of ten residues showed no
inhibitory effect. Such a sequence-specific and con-
centration-dependent inhibition of AOX import sug-
 .gested the presence of some cellular component s
w xthat interacted with the SKL-signal 36 . Although
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biochemical approaches like protein cross-linking,
affinity chromatography, and anti-idiotype antibody
recognition, in combination with the sensitive in vitro
import assay system, have proven useful for the
identification of import machinery components of
w x w xmitochondria 64,65 and chloroplasts 66 , such
methods have not worked for peroxisomes. Alterna-
tively, genetic complementation of yeast mutants de-
fective in the import of proteins with SKL-signal,
PTS1, into peroxisomes has identified a gene, PEX5
w w xxTable 2; for PEX gene nomenclature, see Ref. 67
apparently encoding the PTS1 receptor, in P. pas-
w x w x w xtoris 68 , S. cere˝isiae 69 H. polymorpha 70,71
w xand Yarrowia lipolytica 72 . The PTS1 receptor is a
 .member of the tetratricopeptide repeat TPR family
w xof proteins 73 .
The cDNA encoding the human homolog of PTS1
receptor was independently isolated by an expressed
 .sequence tag EST, see below search with P. pas-
w xtoris PEX5 74 and by the immunoscreening of a
w xcDNA expression library 75 . Human Pex5p encodes
a 67-kDa polypeptide which is also a member of the
TPR protein family and binds to the PTS1 motif in
vitro. An isoform of PTS1 receptor with an insertion
of 37 amino acids between amino acid residues 215–
w x216 was isolated 76,77 . The difference in the
physiological significance of these two isoforms of
w xthe PTS1 receptor is still little known 74,77 . The
intracellular location of PTS1 receptor is still contro-
versial. PTS1 receptor has been localized to the
wcytosol andror associated with peroxisomes 74–
x76,78 .
4.2. PTS2 receptor
 .The S. cere˝isiae pas7 peb1 mutant is defective
only in PTS2-protein import into the peroxisome
w x79,80 . The PEX7 was isolated by the complementa-
tion of the mutant and is thought to encode the
42-kDa PTS2 receptor, a member of the WD repeat
w xfamily of proteins 79,80 . Pex7p apparently binds to
w xthe PTS2 motifs in vivo 81,82 . However, the intra-
cellular location of Pex7p is controversial. Mazioch
w xet al. 79 found it mostly in cytosol and partially
associated with peroxisomes, while Zhang and
w xLazarow 80 localized it inside peroxisomes. It is not
clear as to whether or not the multiple localizations
are linked to the function of this protein. The human
homolog of yeast PEX7 appears to be responsible for
the primary defect in rhizomelic chondrodysplasia
 . wpunctata RCDP Distel et al., unpublished; Gould et
xal., unpublished .
4.3. PTS1 receptor-docking protein
The gene PEX13 of S. cere˝isiae and P. pastoris
and its homologs of human and Caenorhabditis ele-
w xgans, were recently cloned 83,84 . This gene was
Table 2
Genes required for peroxisome biogenesis
PEX S. cere˝isiae P. pastoyis H. polymorpha Y. lipolytica C. boidinii P. anserina Mammals Note
gene PAS PAS PER PAY
PEX 1 1 1 AAA family
2 PER6 5 CAR1 PAF1 PMP, RING finger
3 3 2 9 PMP
4 2 4 ubiquitin-conjugating enzyme
 .5 10 8 3 PAH2 32 PTS1R PTS1 receptor, TPR family
6 8 5 4 PAF2 AAA family
 .7 7 PEB1 PTS2 receptor, WD motif
8 PER3 1
9 2 PMP
10 7 8 PMP, RING finger
11 PMP27 PMP30 peroxisomal proliferation
12 10 PMP, RING finger
13 PEX13 PEX13 HsPEX13 PTS1 receptor-docking factor
14 PEX14 PEX14 PMP
w x w xPMP- peroxisomal membrane protein. Unified nomenclature for PEX genes, PEX1 to PEX13, is from 67 ; PEX14 is from 160,161 .
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also identified by a biochemical study of a peroxiso-
w xmal membrane protein of S. cer˝isiae 85 . PEX13
encodes a peroxisomal, SH3-containing membrane
protein with a molecular mass of 40–43 kDa. The
cytoplasmically oriented SH3 domain apparently
binds to PTS1 receptor. It is of interest to reconstitute
in vitro the PTS1-protein import pathway with
PTS1-polypeptides, PTS1 receptor, PTS1 receptor-
docking protein, and some other factors required.
Models of how Pex5p and Pex7p PTS1 and PTS2
.receptors, respectively recognize signals and trans-
port passenger proteins have recently been presented
w x19,86 .
5. Genetic approaches to studying mammalian
peroxisome biogenesis and its disorders
At present, peroxisomal diseases comprise at least
16 genetically different disorders that are classified
w x into three types 2,16,17,87–90 . These include: Type
.1 , in which peroxisomes are virtually absent and a
generalized impairment of the peroxisomal functions
wis evident cerebrohepatorenal ZS, neonatal
 .adrenoleukodystrophy NALD , and infantile Refsum
 .x  .disease IRD ; Type 2 , in which peroxisomes are
present but several peroxisomal functions are im-
paired RCDP and combined peroxisomal b-oxida-
.  .tion enzyme deficiency ; Type 3 , in which peroxi-
somes are present and only a single peroxisomal
wfunction is impaired X-linked adrenoleukodystrophy
 .  .X-ALD , hyperoxaluria type 1 PH1 , AOX defi-
ciency, trifunctional enzyme deficiency, peroxisomal
3-ketoacyl-CoA thiolase deficiency, dihydroxyace-
 .tonephosphate acyltransferase DHAP-ATase defi-
ciency, alkyl DHAP synthetase deficiency, Refsum
xdisease, and acatalasemia . The pathology and clini-
cal biochemistry of peroxisomal disorders have all
w xbeen recently reviewed 2,16,17 .
Peroxisome-deficient type 1 disorders are consid-
ered to be autosomal recessive and to date have been
reported to include at least ten different genotypes
w x87–90 . These disorders are closely linked to defects
in peroxisome biogenesis. Thus, peroxisome biogene-
sis diseases constitute one model system to elucidate
the genetic causes of inherited human disorders in-
w xvolving protein trafficking defects 91 .
In general, it is difficult to work with specimens
from patients and to manipulate cells such as skin
fibroblasts in order to investigate peroxisome biogen-
esis as well as the pathogenesis and molecular bases
for the primary defects of peroxisomal genetic disor-
ders. Accordingly, mammalian somatic cell mutants
 .such as Chinese hamster ovary CHO mutants that
both phenotypically and genotypically resemble the
cells from patients with these diseases have been
isolated and shown to be very useful for investiga-
tions of peroxisome biogenesis as well as of the
molecular defects of the peroxisomal disorders
w x89,92,93 .
As described above, the genes required for peroxi-
some assembly andror protein import have been
cloned by a functional, genetic complementation of
 .yeast and mammalian cell mutants Table 2 . Nearly
15 genes have thus so far been cloned, primarily with
yeast mutants of S. cere˝isiae, P. pastoris, H. poly-
wmorpha, and Y. lipolytica for reviews, see
w xx18,94,95 . I therefore herein discuss the identifica-
tion of genes related to peroxisome biogenesis and its
disorders in mammalian systems.
5.1. Isolation of peroxisome-deficient mammalian cell
mutants
Two methods have been developed for the isola-
tion of mammalian somatic cell mutants defective in
peroxisome biogenesis: i.e. colony autoradiographic
screening with a phenotypic marker, DHAP-ATase
w xdeficiency 92,93 , and the photosensitized selection
 X .  .method with 9- 1-pyrene nonanol P9OH and long
 . w xwavelength ultraviolet UV light 96 .
5.1.1. Isolation by autoradiographic screening
CHO cell mutants defective in DHAP-ATase, a
key peroxisomal enzyme in the synthesis of ether-lin-
ked glycerolipids such as plasmalogens, are isolated
by a colony autoradiographic screening procedure
w x92 . Mutants deficient in DHAP-ATase cannot con-
vert 32P-labeled DHAP to trichloroacetic acid-in-
soluble palmitoyl-DHAP in the presence of palmi-
toyl-CoA, while normal cells can. Thus mutants can
be isolated by comparing the autoradiograms of cells
grown on filter paper and cell-colony staining. In
mutants, catalase, a matrix enzyme of peroxisomes, is
fully active but not particle-bound. By further mor-
phological and biochemical characterization, isolated
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mutants are found to be defective in peroxisome
assembly, as seen in biopsied tissue and fibroblast
specimens from patients with Zellweger syndrome
w x89,93,97 .
5.1.2. Selection by the P9OHrUV method
A novel method for the direct selection of animal
cell mutants defective in peroxisome biogenesis was
w xdevised by Morand et al. 96 . The procedure is based
on the fact that wild-type animal cells such as CHO
cells incorporate P9OH, a fluorescent, pyrene-labeled
fatty alcohol analogue photosensitizer, into lipids and
thereby become susceptible to photosensitized killing
with oxygen radicals generated by the excitation of
the pyrene with UV light. In contrast, CHO mutants
deficient in plasmalogen andror peroxisomes either
do not incorporate P9OH or do so very poorly and
therefore are rendered resistant to killing by UV light.
Using these two methods, we have isolated three,
phenotypically similar but genotypically distinct, per-
oxisome-deficient CHO cell mutants, Z24 and Z65 by
screening and ZP92 by selection, that resemble fi-
broblasts from patients with peroxisome-deficient
w xdisease 89,93 . Several CHO cell mutant clones of
the same complementation group as Z65 have also
w xbeen isolated by Raetz’s group 97,98 . More re-
cently, several CHO cell mutants, ZP102 and ZP105,
ZP104 and ZP109, ZP110 and ZP111, and ZP114 of
four different complementation groups distinct from
those of Z24, Z65, and ZP92, have been isolated by
w xthe P9OHrUV method 99–101 . The assembly of
peroxisomes is apparently defective in all mutants,
whereas the synthesis of peroxisomal proteins is nor-
mal. Peroxisomal membrane ghosts are seen in all
CHO mutants by immunochemical staining with anti-
body to the 70-kDa peroxisomal integral membrane
 . w xprotein PMP70 102,103 , as reported for fibroblasts
from patients with peroxisome-deficient disease
w x104,105 . The biogenesis of peroxisomal enzymes is
also impaired in the mutants, e.g. AOX is synthesized
normally but rapidly degraded, while 3-ketoacyl-CoA
thiolase is found as an unprocessed but rather stable
w xlarger precursor form 89,93,97,99–101 .
However, in hybrid cells between two of the seven
complementation groups of CHO mutants, the normal
assembly of peroxisomes and the proper biogenesis
of enzymes are evident, as in wild-type cells, thus
suggesting that these mutants contain different le-
sions in the genes encoding factors required for per-
oxisome assembly. Peroxisomes are also detectable in
fusions between wild-type cells and each of the mu-
tants, thereby indicating that the mutations are reces-
sive.
A complete set of complementation analyses by
cell-fusion between the seven complementation
groups of CHO cell mutants and ten groups of cul-
tured skin fibroblasts from patients with peroxisome
assembly disorders revealed that five groups of CHO
mutants, Z24, Z65, ZP92, ZP102rZP105, and
ZP104rZP109 represent the human complementation
Table 3
Complementation groups and complementing genes of mammalian peroxisome deficiency
Human fibroblast Disorder CHO mutant Complementing gene
Japan U.S.A. Europe
Group A VIII ZS, NALD, IRD
B VII ZS
 .C IV 3 ZS ZP92 PEX6 PAF-2
D IX ZS
E I 2 ZS, NALD, IRD Z24
 .F X 5 ZS Z65 PEX2 PAF-1
 .II 4 ZS, NALD ZP102, ZP105 PEX5 PTS1 receptor
III ZS ZP104, ZP109
VI NALD
G
ZP110, ZP111
ZP114
 w x.PEX, unified nomenclature of peroxisome biogenesis genes see Ref. 67 ; ZS, Zellweger syndrome; NALD, neonatal adrenoleukodys-
trophy; IRD, infantile Refsum disease. Complementation group V is no longer available.
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groups E in Japan the same as the largest group I in
. U.S.A. and group 2 in Europe , F the same as group
. X in the USA and group 5 in Europe , C the same as
.group IV in the USA and group 3 in Europe , group
 .II in the USA the same as group 4 in Europe , and
 . w xgroup III, respectively Table 3 89,99,100,106 .
CHO mutants ZP110rZP111 and ZP114 did not fall
into any of the ten human complementation groups,
thus indicating two groups of CHO mutants to be
newly identified as the 11th and 12th mammalian
w xcomplementation groups 101 . Accordingly, perox-
iosme assembly apparently requires at least 12 gene
products in mammals, including humans.
5.2. Cloning of genes required for peroxisome
biogenesis
Factors essential for organelle biogenesis have been
elucidated, including cis-acting topogenic signals such
as the peroxisomal C-terminal SKL motif. However,
little is known of the membrane components involved
in peroxisome assembly. The pathogenic genes re-
sponsible for peroxisome-deficient disorders were first
elucidated in our previous report appeared see be-
.low . The successful isolation of animal cell mutants
prompted us to search for the genes essential for
peroxisome assembly and for human pathogenic genes
by gene transfection and a genetic complementation
analysis.
5.2.1. Peroxisome assembly factor-1
We searched for the gene encoding a factor com-
plementing the defects of one of the CHO cell mu-
tants, Z65, by the transfection of a rat liver cDNA
w xlibrary 107 . Transfectants isolated in the presence of
 X .G418 were selected by the 12- 1-pyrene dodecanoic
 . w xacid P12 rUVrmethod 108 , where ;90% of the
wild-type CHO cells survived but only 0.02% or less
of the peroxisome-defective mutant cells were viable,
presumably due to differences in sensitivity to the
active oxygen compounds generated by UV irradia-
tion. Most P12rUV-resistant cells from the transfec-
tants contained peroxisomes, as assessed by im-
munoflorescence microscopy using anti-catalase anti-
body. An open reading frame, PEX2, in the recov-
ered plasmid encoded a novel 35 kDa protein of 305
amino acids, termed peroxisome assembly factor-1
 . w xPAF-1 107 . Biochemical abnormalities were also
complemented: catalase was latent, DHAP-ATase was
fully active, and the biogenesis of such peroxisomal
enzymes as AOX and thiolase was normal. However,
PEX2 could not complement the CHO mutants, Z24
and ZP92, thereby indicating that the gene lesions in
these mutants are distinct from those of Z65. Indeed,
the PEX6 complements the defects in ZP92 see
.below . Pex2p is predominantly, if not exclusively,
localized to peroxisomes as an integral membrane
protein with N- and C-terminal parts apparently in
the cytosol, which is also consistent with the presence
of two membrane-spanning segments. Pex2p may
function as a component of the transmembrane im-
port machinery of newly synthesized proteins. Pex2p
contains neither a C-terminal SKL motif nor a N-
terminal PTS2 motif, thus implying that Pex2p is
targeted to peroxisomes by another type of topogenic
signal.
Rat, human, and Chinese hamster PEX2s have
w xbeen isolated 98,106,107,109 . Chinese hamster
Pex2p is comprised of 304 amino acids, while human
and rat Pex2ps each have 305 residues. Human PEX2
shows homology to both rat and Chinese hamster
PEX2s, 86% and 90% at the nucleotide level, and
88% and 86% at the deduced amino acid sequence
level, respectively, thereby indicating a high degree
of conservation among PEX2s in these three mam-
malian species. All Pex2ps also contain two mem-
brane-spanning segments, thus suggesting the impor-
tance of these regions for the topology and function
of Pex2p, as assessed in studies of truncation mutants
w x109 . Amino acid residues 2 through 19 at the N-
terminus and residues 214 to 305 in the C-terminal
part do not appear to be essential for the
peroxisome-restoring activity of Pex2p. A cysteine-
rich region in the C-terminal part of Pex2p, at posi-
tions 244 through 305, contains a RING finger motif,
C HC , which is possibly involved in specific pro-3 4
tein-protein interactions through binding with zinc or
w xdivalent metal ions 110 . The RING finger motif is
also encoded in the genes, PEX2 of other species,
w xincluding P. pastoris 111 , the fungus Podospora
w x w x.anserina 112 and Y. lipolytica 113 , PEX10 of H.
w x w xpolymorpha 114 and P. pastoris 115 , PEX12 of
w xP. pastoris 116 , and PAS-4 and -5, which comple-
ment the peroxisome assembly-defective pas mutants
w x  .of yeast S. cere˝isiae 117 Table 2 . The functional
significance of this zinc finger therefore remains to
be determined.
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5.2.2. PEX6
Rat PEX6 encoding peroxisomal assembly factor-2
 .PAF-2 was recently cloned by the functional com-
plementation of another CHO mutant, ZP92, using an
efficient, transient cDNA library-transfection system
w x118 .
Rat Pex6p is 978 amino acids in length and con-
tains two putative ATP-binding sites. Pex6p is a
member of the AAA family ATPases associated
. w xwith diverse cellular activities of ATPases 119 . It is
also noteworthy that several complementing genes
required for yeast peroxisome biogenesis, including
w x w x.PEX1 of S. cere˝isiae 120 and P. pastoris 121
w x w xand PEX6 of S. cere˝isiae 122 , P. pastoris 123 ,
w x.and Y. lipolytica 124 , also belong to this family.
The morphological and biochemical abnormalities
of ZP92 caused by an impaired peroxisome assembly
were restored by rat PEX6. Pex6p is primarily asso-
ciated with the peroxisomal membrane in the rat
liver. Recently, the human Pex6p cDNA was cloned,
and thus encoded a protein of 980 amino acids which
w xwas two residues longer than rat Pex6p 125 . Human
Pex6p shows an 87% identity with rat Pex6p. Human
w xPEX6 is localized on chromosome 6q21.1 125 .
5.3. Expressed sequence tag homology search
An alternative strategy for the isolation of peroxi-
some assembly factor genes has recently been devel-
Fig. 1. Gene products required for peroxisome biogenesis in
mammals. The intracellular locations and molecular properties of
peroxisome biogenesis proteins thus far identified are shown see
.text for details . Two isoforms of PEX5 encoding PTS1 receptor
are identified in humans and Chinese hamster, each comprising
 .  .602 and 595 S , and 639 and 632 L amino acids, respectively.
Pex5p apparently interacts with Pex13p, PTS1 receptor-docking
protein
oped. Candidate genes for mammalian peroxisome
biogenesis, including humans, can be isolated in the
homology search by routinely screening the ex-
 .pressed sequence tag EST database, using yeast
PEX genes. Such an approach has been successfully
applied to cloning human pathogeneic genes, e.g.
w x w x  .PEX5 74 and PEX6 126 see below .
Fig. 1 shows a schematic view of the gene prod-
ucts involved in mammalian peroxisome assembly.
6. Pathogenic genes of peroxisome-deficient dis-
eases
The impaired biogenesis of peroxisomes is likely
to be the primary defect in different peroxisome-defi-
cient disorders comprising ten complementation
groups. This implies that ten or more genes are
wrequired for peroxisome assembly 87–90,99–
x101,106 . Phenotypic properties with respect to the
defects of protein import are characterized using fi-
broblasts from patients of ten complementation groups
w xincluding RCDP of group XI 127,128 . Cells from
NALD patients of complementation group II the
.same as group 4 in Europe are defective in the
transport of PTS1-proteins, while fibroblasts from
RCDP patients of complementation group XI the
.same as group 1 in Europe have an impairment of
the PTS2-specific import pathway. It is noteworthy
that complementation groups III and X are character-
ized as being import deficient for both PTS1- and
PTS2-polypeptides, while other groups show milder
defects in the transport of both types of proteins
w x128 . Similar differential defects of protein transport
w xare noted in CHO cell mutants 77,100 .
The search for the pathogenic genes of peroxi-
some-deficient disorders has been a focus of studies
on peroxisome biogenesis using mutants of mam-
malian cell lines and yeasts.
6.1. PEX2 deficiency disorder
To elucidate the genetic cause of a peroxisome
assembly disorder, rat and human cDNAs encoding
 .Pex2p formerly PAF-1 , were transfected separately
into fibroblasts from a female patient with Zellweger
syndrome of complementation group F the same
.complementation group as group X or 5 , which is in
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w xthe same group as the CHO mutant Z65 106 . Nu-
merous peroxisomes were noted in the Pex2p cDNA
transfected cells, thereby indicating the primary de-
fect of this patient to be a dysfunction of peroxisome
assembly factor-1. Peroxisomal protein biogenesis
defects and deficiency of enzymes such as DHAP-
ATase and b-oxidation of VLCFAs, were also com-
w xplemented by Pex2p 129 . However, no patient fi-
broblasts from other complementation groups were
restored by Pex2p cDNA transfection. The nucleotide
sequence of all patient Pex2p cDNA clones showed a
nonsense point mutation at a CpG dinucleotide, i.e. at
 .119Arg CGA , thus resulting in the creation of a
 . w xpremature termination TGA 105 .
A transfection of the patient Pex2p cDNA did not
restore peroxisome assembly in the patient’s fibrob-
lasts. Accordingly, we concluded that the point muta-
tion of PEX2 was homozygous in the patient Table
.4 . Amplification by PCR and nucleotide sequencing
of parental genomic DNA in the region of the pa-
tient’s PEX2 mutation revealed that both father and
mother were heterozygous for the same site mutation
in PEX2. As a result, the patient inherited the muta-
tion from both parents.
Taken together, for the first time we were able to
identify the primary defect causing a human peroxi-
some-deficient disorder, namely Zellweger syndrome,
and detect its carriers. Several additional patients of
this complementation group have been analyzed by
PCR. One was homozygous for the same point muta-
w xtion at Arg119Ter 19,130 , while another was a
compound heterozygote with mutations Arg119Ter
w xand Arg125Ter 131 . The compound heterozygote
patient inherited one mutation from each parent. We
conducted a prenatal diagnosis of Zellweger syn-
drome using PCR and amniocytes to screen a second
child of the parents whose first offspring had experi-
w xenced the first case of dysfunction of Pex2p 132 .
The mutation in the PEX2 was heterozygous in the
second child and was the same as in the parents. The
second child was diagnosed to be a healthy carrier.
This was the first prenatal carrier detection of Zell-
weger syndrome using a DNA analysis. Such prenatal
diagnoses are now possible. Human PEX2 was as-
w xsigned to chromosome 8q21.1 133 .
6.2. Defect of PEX6
 .Rat cDNA encoding Pex6p formerly PAF-2 was
transfected into fibroblasts from Zellweger patients of
w xcomplementation group C 118 , the same group as
w xCHO mutant ZP92 89 . Peroxisome assembly was
thus morphologically and biochemically comple-
mented in stable transfectants, strongly suggesting
defects in PEX6 to be the pathogenic cause of com-
Table 4
Genetic defects of peroxisome biogenesis factors in peroxisome assembly disorders
 .Gene Chromosomal Product Cellular location Characteristics Disorder Gene defect mutation Ref.
loci size
 .kDa
 . w xPEX2 8q21.1 35 Peroxisome membrane RING finger ZS Arg119Ter Homozygote 106
w xZS Arg119TerrArg125Ter 131
 .Compound heterozygote
 . w xPEX5 12p 13.3 67 Cytosol andror TPR family ZS Arg380Ter Homozygote 74
peroxisome
 . w xAsn489Lys Homozygote 74
w xPEX6 6q21.1 104 Mostly peroxisome AAA family ZS Termination by T 125
membrane insertionrframe shift
 .Homozygote
w xZS One exon deletion by 125
G to A transition
 .Compound heterozygote
w xCytosol Deletions by G to A 126
transition, T insertion
 .Compound heterozygote
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plementation group C group IV in the USA and
.group 3 in Europe .
Pex6p cDNA did not restore the peroxisome as-
sembly in fibroblasts from patients of other comple-
mentation groups. Moreover, human PEX6 comple-
mented abnormalities of not only peroxisome assem-
bly but also of b-oxidation of VLCFAs, in fibrob-
w xlasts from two patients of group C 125 . A gene
analysis of one patient revealed that the genetic basis
of the defects in group C was a homozygous, one
 .base T insertion in the PEX6 at nucleotide residue
511 of a codon for 117Gly the A of the initiating
.ATG being 1 , thus creating a frameshift that results
in premature termination at amino acid residue 235,
far downstream from the insertion position. Patient 2
contained a complete deletion of the 84 base pair-long
exon 3 in one allele of PEX6. This was caused by a
G to A transition at nucleotide 1047, which is a splice
 .acceptor site. Reverse transcription RT -PCR using
RNA from this patient produced two products of
different sizes, a major smaller one and a minor one
with the same size as the control, thereby strongly
suggesting compound heterozygous mutations in the
PEX6.
A human homolog of P. pastoris PEX6 was re-
w xcently isolated by searching the EST database 126 ,
where Pex6p was identical to that isolated by Fukuda
w xet al. 125 , except for the substitution of a few amino
acids and its predominantly cytosolic localization in
fibroblasts. Human Pex6p rescued the peroxisomal
import defect in fibroblasts from patients of comple-
mentation group IV, but not of groups I to III and VII
to X. One patient was concluded to be heterozygous
for two different mutations, an 8 bp deletion at 1962
caused by a G to A transition at a splice acceptor site
and a 20 bp deletion at 2398rsingle T insertion.
These findings by two independent groups thus clearly
demonstrate the molecular cause of the peroxisome
biogenesis defects in group C and IV to be the
mutation of PEX6.
6.2.1. Dysfunction of the PTS1 receptor
The human homolog of P. pastoris PEX5, the
PTS1 receptor gene, was shown to be responsible for
the primary defects in the patients of complementa-
w xtion group II 74,75 . The transfection of human
PTS1 receptor cDNA restored peroxisomal import of
PTS1-proteins in fibroblasts from two patients of
complementation group II, one with ZS and the other
with NALD. The import of both PTS1- and PTS2-
proteins was defective in the ZS patient, while only
the transport of PTS1-proteins was apparently im-
paired in the NALD patient. The mutations in the
PEX5 were Arg390Ter in the ZS patient and
w xAsn489Lys in the NALD patient, respectively 74 .
Pex5p restored import of PTS1- and PTS2-proteins in
w xanother ZS patient 75 . Thus, unlike PEX5-defective
yeast mutants, human PTS1 receptor appears to be
involved in the transport of not only PTS1-proteins
but also of PTS2-proteins such as peroxisomal thio-
lase. The molecular basis of this difference remains
to be solved. Similar findings have been noted in
recently isolated CHO mutant cells of complementa-
w xtion group II 77,100 . Human PEX5 was assigned to
w xchromosome 12p13.3 75 .
6.2.2. Other pathogenic genes of peroxisome biogen-
esis disorders
w xPMP70 102 , a member of the ABC transporter
ww x xsuperfamily 103 , see below , was proposed to be
involved in the pathogenesis of a peroxisome-defi-
w xcient disease 134 .
Out of 21 patients of one complementation group
 . the largest group I in USA , two point mutations a
.donor splice site mutation and a missense mutation
in the gene for PMP70, one of each mutation in one
allele of two patients with ZS, were noted. The
incidence of only two cases out of 21 patients is
w xapparently a paradox. Shimozawa et al. 129 re-
ported that peroxisome assembly was not compli-
mented by a stable transfection of a human cDNA
encoding PMP70 into fibroblasts from seven patients,
four with ZS and three with IRD of complementation
 .group I the same as group E in Japan . The func-
tional significance of PMP70 in peroxisome biogene-
sis therefore remains ambiguous.
7. Dysfunction of a single enzyme protein
Peroxisomal disorders characterized by morpho-
logically normal peroxisomes but deficiencies of a
single enzyme include the most common X-ALD,
PH1, b-oxidation enzyme deficiency, DHAP-ATase
deficiency, alkyl DHAP synthetase deficiency, Ref-
sum disease, and acatalasemia. Significant progress
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has been reported in defining the primary defects of
several of these diseases.
7.1. X-linked adrenoleukodystrophy
X-ALD is accompanied by severe cerebral de-
myelination and the accumulation of VLCFAs caused
by an impairment of peroxisomal b-oxidation of
VLCFAs, evidently due to defects in very long chain
 . w xfatty acyl-CoA synthetase ligase 135 . A positional
cloning strategy enabled Aubourg and associates to
w xclone a gene responsible for this disease 136,137 .
This gene encodes a 75-kDa peroxisomal membrane
 .protein, termed ALD protein ALDP , with signifi-
w xcant homology to PMP70 102,134 of the ATP-bind-
 .ing cassette ABC membrane transporter superfam-
w xily 138 . ALDP may play a role in the transport or
activation of VLCFA-CoA synthetase, whose activity
is defective in ALD. Although ALDP is barely de-
tectable in fibroblasts from X-ALD patients, it is of
interest that ALDP is apparently associated with per-
oxisomal ghosts in fibroblasts from Zellweger pa-
tients defective in VLCFA oxidation. Expression of
ALDP cDNA in fibroblasts from X-ALD patients
corrected defective VLCFA oxidation, possibly open-
ing a way to gene therapy by a similar approach
w xusing hematopoietic cells 139,140 .
7.2. Hyperoxaluria type 1
PH1 is caused by a defect of a peroxisomal en-
 .zyme, alanine:glyoxylate aminotransferase AGT
 . w xalso called serine:pyruvate aminotransferase 141 .
In a subset of PH1 patients, AGT is mistargeted to
mitochondria, where detoxification of glyoxylate by
w xconversion to glycine fails to occur 142 . Common
 .point mutations, Pro11Leu base C mutated to T ,
 .  .Gly170Arg G to A , and Ile340Met A to G , which
potentially create an N-terminal mitochondrial target-
ing signal and thus result in the retardation of AGT
dimerization in the cytosol, were noted in PH1 pa-
w x  .tients 143,144 . A point mutation Ser206Pro also
apparently enhanced the cellular degradation of AGT
w x145 . AGT may thus serve as a model protein to
study the significance of polypeptide configuration,
including tertiary structure, in targeting to a subcellu-
lar compartment.
7.3. b-Oxidation enzyme deficiency
Patients with deficiency of a single enzyme of the
w xperoxisomal b-oxidation system, AOX 146 , trifunc-
w xtional protein 147 , and 3-ketoacyl-CoA thiolase
w x148 , have been recently described. The total ab-
sence of enzymes in these respective disorders is not
the only reason for the loss of enzyme activity. Some
 .mutation s may affect only the activity of the en-
zyme.
7.4. DHAP-ATase deficiency, alkyl DHAP synthetase
deficiency
Biochemical studies of patients with a deficiency
of DHAP-ATase or alkyl DHAP synthetase show a
moderate reduction of both the plasmalogen levels in
plasma and plasmalogen synthesis in skin fibroblasts.
However, the anomalies are much less severe than
w xthose in RCDP 87,149,150 . A complementation
analysis by fusion of DHAP-ATase deficient cells
and alkyl DHAP synthetase deficient cells revealed
w xtwo distinct complementation groups 149,150 . The
genetic bases of the deficiencies of these two en-
zymes have yet to be identified. Although DHAP-
ATase and alkyl DHAP synthetase have not been
purified, molecular cloning of the genes encoding
these enzymes may elucidate the primary defects in
these disorders.
7.5. Refsum disease
Refsum disease is a rare neurological autosomal
inherited metabolic disorder. It is characterized by
peripheral neuropathy, retinitis pigmentosa, and
pathognomonic accumulation of phytanic acid in both
body fluids and tissue, due to a defect in the a-oxida-
tion of phytanic acid, a chlorophyll metabolite, to
w xpristanic acid 151,152 . A deficiency of peroxisomal
hydroxylation of phytanic acid has been seen in the
w xfibroblasts from Refsum patients 152 . The molecu-
lar basis for the loss of phytanic acid a-hydroxylase
activity remains to be elucidated. It is noteworthy that
phytanic acid binds and activates a nuclear receptor,
PXR, with a possible involvement in the RXR-depen-
w xdent signaling pathways 153 . Elevated levels of
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phytanic acid may thus affect such signaling path-
ways.
7.6. Acatalasemia
Classical human acatalasemia is a genetic defi-
w xciency of erythrocyte catalase 154 , but it is some-
times described as a condition in which peroxisomal
w xcatalase is deficient 2,16,17 . The disease was first
w xfound in Japan and later in Switzerland 155 . The
catalase gene consists of 13 exons and 12 introns
w x156 . The genetic defect in two Japanese patients
was suggested to be a G to A transition at the fifth
position of intron 4, which severely limits correct
w xgene splicing 157 .
8. Outlook
The identification and characterization of numer-
ous genes that are essential for peroxisome biogene-
sis by means of the genetic complementation of
peroxisome assembly-defective mutants of mam-
malian somatic cells, such as CHO cells, and of
several yeast species including S. cere˝isiae, P. pas-
toris, H. polymorpha, and Y. lipolytica, have made
invaluable contributions to the study of peroxisome
w xbiogenesis 18–21,86,94,119,158 and protein traf-
w xficking in eukaryotes 159 . While the biochemical
 .functions of most of these genes or gene products in
peroxisome biogenesis remain to be elucidated at
molecular level, delineation of the more pathogenic
genes responsible for peroxisome deficiency disor-
ders could be accomplished by several genetic ap-
proaches, including those described in this review.
One direct and useful approach is the molecular
cloning of more peroxisome biogenesis factors by the
genetic complementation of additional peroxisome
assembly mutants of CHO cells belonging to other
complementation groups.
Direct complementation by the peroxisome bio-
genesis factor of peroxisomal abnormalities in fibrob-
lasts from patients of the same complementation group
as the CHO mutant would thus also be evidence that
the peroxisome biogenesis factor is defective in the
human complementation group, as was the case for
the PEX2 and PEX6 deficiency disorders. Recently
isolated CHO mutants distinct from Z24, Z65, and
w xZP92 may be useful in such an approach 99–101 .
More direct genetic complementation assays using
patient fibroblasts may become feasible by simplified
cell staining, such as microscopy of the unfixed cells
expressing a fluorescent marker, e.g. jellyfish green
fluorescent protein, even though the current genetic
manipulation techniques may still be improved. An-
other direct approach would be an EST search which
has recently been successfully employed in the
cloning of the cDNA for the human PTS1 receptor by
w xsearching with P. pastoris PEX5 74 . Future experi-
ments will hopefully identify other types of PTSs
other than PTS1 and PTS2, protein translocation
machinery and its reconstitution, cytosolic factors,
chaperones, etc. Given that a great deal of informa-
tion will soon be forthcoming, it may not be long
before a complete picture of peroxisome biogenesis
and its disorders at the molecular level is obtained.
Analysis of the pathogenic genes responsible for
peroxisomal disorders would facilitate prenatal diag-
noses by a DNA analysis, as is now available for
PEX2, PEX5, and PEX6. By constructing transgenic
animals with knocked-out peroxisome biogenesis fac-
tor genes or PEX genes replaced with patient
pathogenic genes, issues such as the relationship
between impaired peroxisome biogenesis and patho-
genesis and the significance of peroxisomes in devel-
opmental processes such as neural migration, can
thus be better understood. In the future, investigators
should thus be able to shed some more light on the
ultimate goal, the treatment and gene therapy of
patients with peroxisome biogenesis disorders.
Note added: During the revision of this manuscript,
the mutations of PEX7 and PEX12 were shown to
be responsible for rhizomelic chondysplasia punctata
w x162–164 and the peroxisome-deficient disorders of
w xcomplementation group III 165,166 .
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